Search
Sabiporide
go.drugbank.com/drugs/DB21244ExperimentalSabiporide is a small molecule drug. The usage of the INN stem '-poride' in the name indicates that Sabiporide is a Na+/H+ antiport inhibitor.
Foropafant
go.drugbank.com/drugs/DB21304ExperimentalForopafant is a small molecule drug. The usage of the INN stem '-pafant' in the name indicates that Foropafant is a platelet-activating factor antagonist.
Cloxacepride
go.drugbank.com/drugs/DB21428ExperimentalCloxacepride is a small molecule drug. The usage of the INN stem '-pride' in the name indicates that Cloxacepride is a sulpiride derivative and analogue.
Bofutrelvir
go.drugbank.com/drugs/DB21501ExperimentalBofutrelvir is a small molecule drug. The usage of the INN stem '-trelvir' in the name indicates that Bofutrelvir is a antiviral 3CL protease inhibitor.
Ulecaciclib
go.drugbank.com/drugs/DB21595ExperimentalUlecaciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Ulecaciclib is a cyclin dependant kinase inhibitor.
Eciruciclib
go.drugbank.com/drugs/DB21597ExperimentalEciruciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Eciruciclib is a cyclin dependant kinase inhibitor.
Zevotrelvir
go.drugbank.com/drugs/DB21638ExperimentalZevotrelvir is a small molecule drug. The usage of the INN stem '-trelvir' in the name indicates that Zevotrelvir is a antiviral 3CL protease inhibitor.
Orenasitecan
go.drugbank.com/drugs/DB21718ExperimentalOrenasitecan is a small molecule drug. The usage of the INN stem '-tecan' in the name indicates that Orenasitecan is a antineoplastic, topoisomerase I inhibitor.
Mocaciclib
go.drugbank.com/drugs/DB21730ExperimentalMocaciclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Mocaciclib is a cyclin dependant kinase inhibitor.
Fecal microbiota
go.drugbank.com/drugs/DB17743ApprovedInvestigational[A259167,A259182] The use of fecal microbiota transplantation is a treatment alternative for patients with recurrent CDI, also associated with lower costs and patient waiting times. … [A259172] REBYOTA, a live fecal microbiota suspension for rectal use, was approved by the FDA in November 2022.